Utility of the Plasma Level of suPAR in Monitoring Risk of Mortality during TB Treatment

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Rabna, Paulo ^a   Andersen, Andreas ^a   Wejse, Christian ^a,b,c   Oliveira, Ines ^d   Gomes, Victor Francisco ^a   Haaland, Maya Bonde ^c   Aaby, Peter ^a,e   Eugen Olsen, Jesper ^a  

^a Studies of the Epidemiology of Epilepsy in Demographic Surveillance Systems   (Guinea-Bissau)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c AARHUS UNIVERSITY   (Denmark)

^d HVIDOVRE HOSPITAL   (Denmark)

^e STATENS SERUM INSTITUT   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; SOLUBLE UROKINASE RECEPTOR; UNCLASSIFIED DRUG; UROKINASE RECEPTOR;

ADULT; AGE; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; DRUG EFFICACY; DRUG SAFETY; ETHNICITY; FEMALE; FOLLOW UP; GENDER; HUMAN; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATIENT MONITORING; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SOCIOECONOMICS; SPUTUM SMEAR; TREATMENT DURATION; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTITUBERCULAR AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; RISK; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

EID: 84865499900     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0043933     Document Type: Article

References (33)

1. Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, et al. (2003) The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 163(9): 1009-1021.
2. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC, (1999) Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 282(7): 677-686.
3. WHO (2004). Global Tuberculosis Control. Surveillance, Planning and Financing. WHO Report. Geneva, Switzerland World Health Organization: 1-218.
4. Gustafson P, Gomes VF, Vieira CS, Rabna P, Seng R, et al. (2004) Tuberculosis in Bissau: incidence and risk factors in an urban community in sub-Saharan Africa. Int J Epidemiol 33(1): 163-172.
5. Plesner T, Behrendt N, Ploug M, (1997) Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR. Stem Cells 15(6): 398-408.
6. Ploug M, (2003) Structure-function relationships in the interaction between the urokinase-type plasminogen activator and its receptor. Curr Pharm Des 9(19): 1499-1528.
7. Nykjaer A, Moller B, Todd RF 3rd, Christensen T, Andreasen PA, et al (1994) Urokinase receptor. An activation antigen in human T lymphocytes. J Immunol 152(2): 505-516.
8. Plesner T, Ralfkiaer E, Wittrup M, Johnsen H, Pyke C, et al. (1994) Expression of the receptor for urokinase-type plasminogen activator in normal and neoplastic blood cells and hematopoietic tissue. Am J Clin Pathol 102(6): 835-841.
9. Coleman JL, Gebbia JA, Benach JL, (2001) Borrelia burgdorferi and other bacterial products induce expression and release of the urokinase receptor (CD87). J Immunol 166(1): 473-480.
10. Coleman JL, Benach JL, (2003) The urokinase receptor can be induced by Borrelia burgdorferi through receptors of the innate immune system. Infect Immun 71(10): 5556-5564.
11. Dekkers PE, ten Hove T, te Velde AA, van Deventer SJ, van Der Poll T, (2000) Upregulation of monocyte urokinase plasminogen activator receptor during human endotoxemia. Infect Immun 68(4): 2156-2160.
12. Juffermans NP, Dekkers PE, Verbon A, Speelman P, van Deventer SJ, et al. (2001) Concurrent upregulation of urokinase plasminogen activator receptor and CD11b during tuberculosis and experimental endotoxemia. Infect Immun 69(8): 5182-5185.
13. Kirchheimer JC, Nong YH, Remold HG, (1998) IFN-gamma, tumor necrosis factor-alpha, and urokinase regulate the expression of urokinase receptors on human monocytes. J Immunol 141(12): 4229-4234.
14. Sitrin RG, Todd RF, 3rd, Mizukami IF, Gross TJ, Shollenberger SB, et al (1994) Cytokine-specific regulation of urokinase receptor (CD87) expression by U937 mononuclear phagocytes. Blood 84(4): 1268-1275.
15. Alfano M, Sidenius N, Blasi F, Poli G, (2003) The role of urokinase-type plasminogen activator (uPA)/uPA receptor in HIV-1 infection. J Leukoc Biol 74(5): 750-756.
16. de Bock CE, Wang Y, (2004) Clinical significance of urokinase-type plasminogen activator receptor (uPAR) expression in cancer. Med Res Rev 24(1): 13-39.
17. Eugen-Olsen J, Gustafson P, Sidenius N, Fischer TK, Parner J, et al. (2002) The serum level of soluble urokinase receptor is elevated in tuberculosis patients and predicts mortality during treatment: a community study from Guinea-Bissau. Int J Tuberc Lung Dis 6(8): 686-692.
18. Florquin S, van den Berg JG, Olszyna DP, Claessen N, Opal SM, (2001) Release of urokinase plasminogen activator receptor during urosepsis and endotoxemia. Kidney Int 59(6): 2054-2061.
19. Ostrowski SR, Piironen T, Hoyer-Hansen G, Gerstoft J, Pedersen BK, et al. (2005) Reduced release of intact and cleaved urokinase receptor in stimulated whole-blood cultures from human immunodeficiency virus-1-infected patients. Scand J Immunol 61(4): 347-356.
20. Ostrowski SR, Ullum H, Goka BQ, Hoyer-Hansen G, Obeng-Adjei G, et al. (2005) Plasma concentrations of soluble urokinase-type plasminogen activator receptor are increased in patients with malaria and are associated with a poor clinical or a fatal outcome. J Infect Dis 191(8): 1331-1341.
21. Perch M, Kofoed P, Fischer TK, Co F, Rombo L, et al. (2004) Serum levels of soluble urokinase plasminogen activator receptor is associated with parasitemia in children with acute Plasmodium falciparum malaria infection. Parasite Immunol 26(5): 207-211.
22. Sidenius N, Sier CF, Ullum H, Pedersen BK, Lepri AC, et al. (2000) Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection. Blood 96(13): 4091-4095.
23. Slot O, Brunner N, Locht H, Oxholm P, Stephens RW, (1999) Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: increased concentrations in rheumatoid arthritis. Ann Rheum Dis 58(8): 488-492.
24. Wittenhagen P, Kronborg G, Weis N, Nielsen H, Obel N, et al. (2004) The plasma level of soluble urokinase receptor is elevated in patients with Streptococcus pneumoniae bacteraemia and predicts mortality. Clin Microbiol Infect 10(5): 409-415.
25. Lawn SD, Myer L, Bangani N, Vogt M, Wood R, (2007) Plasma levels of soluble urokinase-type plasminogen activator receptor (suPAR) and early mortality risk among patients enrolling for antiretroviral treatment in South Africa. BMC Infect Dis 7: 41.
26. Huttunen R, Syrjänen J, Vuento R, Hurme M, Huhtala H, et al. (2011) Plasma level of soluble urokinase-type plasminogen activator receptor as a predictor of disease severity and case fatality in patients with bacteraemia: a prospective cohort study. J Intern Med 270(1): 32-40.
27. Koch A, Voigt S, Kruschinski C, Sanson E, Dückers H, et al. (2011) Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients. Crit Care 15(1): R63.
28. Djoba Siawaya JF, Bapela NB, Ronacher K, Veenstra H, Kidd M, et al. (2008) Immune parameters markers of tuberculosis extent of disease and early prediction of anti-tuberculosis chemotherapy response. Journal of Infection 56(5): 340-7.
29. Rabna P, Andersen A, Wejse C, Oliveira I, Gomes VF, et al. (2009) High mortality risk among individuals assumed to be TB-negative can be predicted using a simple test. Trop Med Int Health 14: 986-994.
30. Eugen-Olsen J, Andersen O, Linneberg A, Ladelund S, Hansen TW, et al. (2010) Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population. J Intern Med 268(3): 296-308.
31. Wei C, El Hindi S, Li J, Fornoni A, Goes N, et al. (2011) Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med17(8): 52-60.
32. Haupt TH, Petersen J, Ellekilde G, Klausen HH, Thorball CW, et al. (2012) suPar levels are associated with mortality, admission time, and Charlson Comorbidity Index in the acutely admitted medical patient: a prospective observational study. Crit Care 16: R130.
33. Wejse C, Gustafson P, Nielsen J, Gomes VF, Aaby P, et al. (2008) TBscore: Signs and symptoms from tuberculosis patients in a low-resource setting have predictive value and may be used to assess clinical course. Scand J Infect Dis 40(2): 111-20.